Expression and production of interleukin 10 in human myeloma cell lines
- PMID: 11122145
Expression and production of interleukin 10 in human myeloma cell lines
Abstract
Recent investigations of the cytokine network surrounding myeloma cells have disclosed the importance of gp130-related cytokines including interleukin (IL)-6 for myeloma cell survival and proliferation, identification of IL-10 as a growth factor for myeloma cells, the close relationship between IL-10 and the receptors for gp130-related cytokines, and the growth enhancement effect of IL-11 and IL-7 on myeloma cells. In this study, IL-10 production was observed in three out of seven human myeloma cell lines examined and five (including three producing lines) out of 10 lines exhibited mRNA expression of IL-10. The IL-10 mRNA expression was also enhanced in approximately one third of primary specimens, whereas the IL-10 receptor (R) expression was not changed compared with that of normal component marrow controls. However, reverse transcription-polymerase chain reaction (RT-PCR) assay of various cytokines and their receptors showed no particular association with IL-10-producing myeloma lines compared with non-producing lines. Supplementing exogenous IL-10 or neutralization of the IL-10 signal by anti-IL-10 monoclonal antibody (mAb) in a culture conditions did not significantly affect myeloma cell growth regardless of expression of IL-10 or its receptor (IL-10R). However, supplement of anti-IL-10 mAb caused upregulation of certain genes such as IL-11, leukaemia inhibitory factor receptor (LIFR) and syndecan-1 in IL-10R-expressing cell lines. These findings indicate that the cytokine network surrounding myeloma cells is complicated and variable. In addition, IL-10 may modify this network and the cellular biological properties of myeloma cells rather than cell proliferation.
Similar articles
-
Growth regulatory pathways in myeloma. Evidence for autocrine oncostatin M expression.J Immunol. 1996 Oct 1;157(7):3081-8. J Immunol. 1996. PMID: 8816418
-
FR901228, an inhibitor of histone deacetylases, increases the cellular responsiveness to IL-6 type cytokines by enhancing the expression of receptor proteins.Oncogene. 2002 Sep 12;21(41):6264-77. doi: 10.1038/sj.onc.1205777. Oncogene. 2002. PMID: 12214267
-
A ciliary neurotrophic factor-sensitive human myeloma cell line.Exp Hematol. 1996 Aug;24(10):1195-200. Exp Hematol. 1996. PMID: 8765494
-
Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma.Eur Cytokine Netw. 1990 Oct-Nov;1(4):193-201. Eur Cytokine Netw. 1990. PMID: 2104241 Review.
-
[Cytokines and lymphoplasmocytic proliferations: essential role of interleukin 6].Rev Prat. 1993 Feb 1;43(3):275-8. Rev Prat. 1993. PMID: 8502954 Review. French.
Cited by
-
B-cell targeting agents in the treatment of multiple sclerosis.Curr Treat Options Neurol. 2013 Jun;15(3):259-69. doi: 10.1007/s11940-013-0232-y. Curr Treat Options Neurol. 2013. PMID: 23609780 Free PMC article.
-
Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells.Arch Immunol Ther Exp (Warsz). 2008 May-Jun;56(3):207-21. doi: 10.1007/s00005-008-0022-5. Epub 2008 May 30. Arch Immunol Ther Exp (Warsz). 2008. PMID: 18512025 Free PMC article.
-
The Immune Microenvironment in Multiple Myeloma: Friend or Foe?Cancers (Basel). 2021 Feb 5;13(4):625. doi: 10.3390/cancers13040625. Cancers (Basel). 2021. PMID: 33562441 Free PMC article. Review.
-
Metabolic Effects of Recurrent Genetic Aberrations in Multiple Myeloma.Cancers (Basel). 2021 Jan 21;13(3):396. doi: 10.3390/cancers13030396. Cancers (Basel). 2021. PMID: 33494394 Free PMC article. Review.
-
Overcoming the Immunosuppressive Tumor Microenvironment in Multiple Myeloma.Cancers (Basel). 2021 Apr 22;13(9):2018. doi: 10.3390/cancers13092018. Cancers (Basel). 2021. PMID: 33922005 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous